Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant. - Wikidata - wikimedia - TriplyDB

Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.

Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.

http://www.wikidata.org/entity/Q37452772

about

Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets.Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.A self-assembling peptide acting as an immune adjuvant.Coadministration of polyinosinic:polycytidylic acid and immunostimulatory complexes modifies antigen processing in dendritic cell subsets and enhances HIV gag-specific T cell immunity.An overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccines Long-term antibody and immune memory response induced by pulmonary delivery of the influenza Iscomatrix vaccine ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway.Meta-Analysis on Randomized Controlled Trials of Vaccines with QS-21 or ISCOMATRIX Adjuvant: Safety and Tolerability.Off-the-shelf adenoviral-mediated immunotherapy via bicistronic expression of tumor antigen and iMyD88/CD40 adjuvant Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity.Vaccine adjuvants: putting innate immunity to work.The CD8⁺ T Cell-Mediated Immunity Induced by HPV-E6 Uploaded in Engineered Exosomes Is Improved by ISCOMATRIXTM Adjuvant.Novel adjuvants & delivery vehicles for vaccines development: a road ahead Melanoma vaccines: developments over the past 10 years.Adjuvanted influenza vaccines.Adjuvants for foot-and-mouth disease virus vaccines: recent progress.Trans-sialidase overcomes many antigens to be used as a vaccine candidate against Trypanosoma cruzi.CpG ODN and ISCOMATRIX adjuvant: a synergistic adjuvant combination inducing strong T-Cell IFN-γ responses Development and assessment of a new cage-like particle adjuvant.Slc15a4 function is required for intact class switch recombination to IgG2c in response to TLR9 stimulation.Translational nanoparticle engineering for cancer vaccines.Quillaja brasiliensis saponin-based nanoparticulate adjuvants are capable of triggering early immune responses

P2860

Q28393754-451D5421-6B60-4A5F-98E6-CDA278825481 Q28647225-CA8E3BC6-A61C-4C8F-A758-CC9063968231 Q30372696-75B3D44B-F026-4C73-A43E-6388DE65C979 Q31138173-DEFED6F1-123D-4783-A0E2-CA68B1F67E69 Q33640064-43655ABE-4F72-4AD9-9FB7-56DFF74C66FB Q33909362-CC3DD43F-5B1E-4EE0-BC10-8CA9BC4807E6 Q35100779-A125BBCC-96CB-4EAC-9305-A258CEFD8CE8 Q35666175-87DFBFB8-615D-4987-BD03-79AC63DD5D6F Q36001701-4B58A1BF-9AF5-4CCB-B813-510CE13E1A10 Q36009558-D5AB05B8-A835-4EEB-ADD6-1C7E30454E7F Q36085370-0ED68930-E8D0-4C5F-8CB1-866130BE09D9 Q36094699-9343134D-0E89-4A45-8F31-E00D380007F6 Q36168232-E2DD7902-1F88-46EB-85EF-419B2833ECDD Q37539231-A8E44966-9043-4B33-9557-B7DEF06F46BE Q37592383-3ABCCDEC-3799-44F3-AE2D-85A4425AC4A1 Q37892595-806A5A08-7D2B-49D5-80AC-4B6F5659BB64 Q37976540-65C90232-4955-4219-8DEF-50FCE39DEC69 Q38252451-483B43C3-4D57-4910-BCD6-FE0148024F2B Q38735876-B72184BE-0D35-4194-AE91-AA3C63CEFF11 Q39657741-F8A1D4CF-01DD-40EC-8771-B822929DEEB7 Q40152711-5D277D8F-63A7-4B3A-B7A4-AF780134DE1A Q42183787-0AC4AE0C-8D6F-4022-B9C9-B6B3E48B8D51 Q46720677-303D7C87-CF11-44FA-8E64-8DDC789030C5 Q58751640-8A33A3C1-6082-43AD-A846-E4CD0C45DD4C

P2860

Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.

http://www.wikidata.org/entity/Q37452772

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 April 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.

@en

Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.

@nl

type

label

Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.

@en

Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.

@nl

prefLabel

Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.

@en

Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.

@nl

P1433

Q37452772-63768FB3-56BC-4DCB-AD27-AABC4AD0BFD3

P1476

Q37452772-B97FC2DC-21AB-4C84-9599-903BC4B31B01

P2093

Q37452772-1F4D4C83-C3CF-4155-98A4-69B9DA34E320

Q37452772-2349BD08-938E-40E7-94F1-408285F6E7F8

Q37452772-2DE45E26-F038-42E5-9878-2C892A7C57F2

Q37452772-5D91C448-0DD1-4BAD-BE0E-01286AFF51BF

Q37452772-78D0B385-BF68-4F95-9ED7-0673FF43EFC6

Q37452772-C83BE76A-60FF-4115-9AA0-3274721B2AE4

P2860

Q37452772-0584AF8C-E587-4E50-9D3B-76A596895712

Q37452772-06ECB5AA-ACC3-44BA-BC6B-1B6BA31A0CA8

Q37452772-0BC20F39-A6BE-492F-9322-A6BAEA990AF8

Q37452772-14161E3D-08AF-4A0F-B7EC-7464B4EADB64

Q37452772-1B231C23-71DF-43CF-B63B-39C6FB96EEE3

Q37452772-209A5655-BE12-4D3E-9A1C-1FFD1C550867

Q37452772-29293EE6-C577-4D56-8AEC-FE1D93F1A35B

Q37452772-2B1B859E-EF11-4B62-88A0-EC9FE3CB5243

Q37452772-2CE317AE-67A4-4895-BA7B-99AB02AC176F

Q37452772-3C2CBCA9-DEDA-43C4-B4D1-E8E8DD6AB34E

P304

Q37452772-45BA544A-3150-4523-9348-94A2D9F20003

P31

Q37452772-CC5526B8-FF3E-4AF5-9324-CA08EF918B4B

P356

Q37452772-898750CB-B176-4B3B-A644-B23F234D7E81

P433

Q37452772-F990F6E4-1790-4BA5-B1D8-986BF3B3522A

P478

Q37452772-6D8CEDE6-0F7A-4D80-AEF4-3E5B40FA663D

P577

Q37452772-4B3033D7-B9B6-402E-A016-6F59E5C5C0FF

P5875

Q37452772-61F393E8-511B-4C3A-850B-3E192C0B87D9

P698

Q37452772-18A949B0-AB5B-4157-863E-BCE223FF870C

P356

P1433

Immunology & Cell Biology

P1476

Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.

@en

P2093

Debbie Drane

http://www.w3.org/2001/XMLSchema#string

Eugene Maraskovsky

http://www.w3.org/2001/XMLSchema#string

Jeff Boyle

http://www.w3.org/2001/XMLSchema#string

Max Schnurr

http://www.w3.org/2001/XMLSchema#string

Neil C Robson

http://www.w3.org/2001/XMLSchema#string

Nick S Wilson

http://www.w3.org/2001/XMLSchema#string

P2860

Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations.

Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2

Cancer/testis antigens: an expanding family of targets for cancer immunotherapy

The utility of ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring antibody responses.

MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.

Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay.

Immune responses to ISCOM formulations in animal and primate models.

Resiquimod and other immune response modifiers as vaccine adjuvants.

Recent advances in the discovery and delivery of vaccine adjuvants.

Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII.

P304

371-376

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/ICB.2009.21

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

87

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24311991

http://www.w3.org/2001/XMLSchema#string

P698

19381160

http://www.w3.org/2001/XMLSchema#string